Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

10612studies shown

Showing 2,269-2,280 of 10,612

Drug study icon

TerminatedNCT03900754

A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 70 Years

Countries: United States
Sponsor: VA Office of Research and Development
Condition: Schizophrenia

Drug study icon

WithdrawnNCT06711640

A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionDrugFrom 12 Years to 18 Years

Countries: United States
Sponsor: USWM, LLC (dba US WorldMeds)
Condition: Addiction

Biological study icon

CompletedNCT02189057

A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression

This summary needs review. Please check the official study record and contact the research team for details.

In United States

Depression, BipolarityOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: Mayo Clinic
Condition: Depression, Bipolarity

Drug study icon

CompletedNCT02804568

Safety Study in Adults With Schizophrenia

This study is completed in the United States. It focuses on schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: Alkermes, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT02477020

TAK-063 for schizophrenia

This study is completed in the United States. It is testing TAK-063 for schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Takeda
Condition: Schizophrenia

Drug study icon

TerminatedNCT06673368

Parallel, Adaptive-Design, study Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

This study was terminated in the United States. It focuses on ADHD.

In United States

ADHDDrugFrom 13 Years to 17 Years

Countries: United States
Sponsor: Neurocentria, Inc.
Condition: ADHD

Drug study icon

CompletedNCT05193409

BNC210 for anxiety

This study is completed in the United States. It is testing BNC210 for anxiety.

In United States

AnxietyDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Bionomics Limited
Condition: Anxiety

Drug study icon

CompletedNCT01678755

ABT-126 for schizophrenia

This study is completed in the United States. It is testing ABT-126 for schizophrenia.

In United States

SchizophreniaDrugFrom 20 Years to 55 Years

Countries: United States
Sponsor: AbbVie (prior sponsor, Abbott)
Condition: Schizophrenia

Drug study icon

CompletedNCT04158687

Safety and Efficacy of CTP-692 for schizophrenia

This study is completed in the United States. It is testing Safety and Efficacy of CTP-692 for schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: Concert Pharmaceuticals
Condition: Schizophrenia

Drug study icon

CompletedEUCTR 2018-003825-27

A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United States

SchizophreniaDrugFrom 18 Years to 55 Years

Countries: United States, United Kingdom, Germany, ...
Sponsor: Biogen Idec Research Limited
Condition: Schizophrenia

Drug study icon

CompletedNCT04951076

Study of BNC210 Tablet Formulation in Adults With PTSD (PTSD)

This summary needs review. Please check the official study record and contact the research team for details.

In United States

PTSDDrugFrom 18 Years to 75 Years

Countries: United States, United Kingdom
Sponsor: Bionomics Limited
Condition: PTSD

Drug study icon

TerminatedNCT03841773

TNX-102 SL for PTSD

This study was terminated in the United States. It is testing TNX-102 SL for PTSD.

In United States

PTSDDrugFrom 18 Years to 75 Years

Countries: United States
Sponsor: Tonix Pharmaceuticals, Inc.
Condition: PTSD

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.